Form 4: Oncocyte Corp CFO Andrea James Reports Acquisition of Restricted Stock Units

Andrea James, CFO of Oncocyte Corp, reports the acquisition of 113,207 restricted stock units.

Summary

• On March 26, 2025, Andrea James, the Chief Financial Officer of Oncocyte Corp, reported the acquisition of 113,207 restricted stock units.
• These restricted stock units vest in four equal installments, with 25% vesting annually over four years from the grant date, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of restricted stock units indicates confidence in the CFO's continued service and contribution to the company's success.

Positives

• The vesting schedule incentivizes long-term commitment from the CFO.

Future Outlook

The vesting schedule of the restricted stock units suggests an expectation of continued service and contribution from the CFO over the next four years.

Industry Context

This is a standard practice for incentivizing and retaining key executives in publicly traded companies.

Comparison to Industry Standards

• Granting restricted stock units to executives is a common practice in the biotechnology industry to align their interests with those of shareholders.
• Vesting schedules of four years are typical for such grants, ensuring long-term commitment.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning management's interests with the company's long-term performance.
• Employees may see this as a sign of stability and commitment from the leadership team.

Key Dates

Keywords

restricted stock units, Form 4, insider trading, Oncocyte Corp, Andrea James, OCX, CFO, beneficial ownership